[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports 27% Reduction In COPD Exacerbations In Phase 3 Trial",
    "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) announced favorable Phase 3 trial results for itepekimab and entered a significant licensing agreement with Telesis Bio, enhancing its R&D capabilities. Despite these positive developments, the company's shares fell by 17% last week. In contrast, the broader market rose by 1.7%. This divergence might suggest that the market's reaction to Regeneron's news was mixed or that other factors were at play. While the trial success and new partnership could...",
    "url": "https://finnhub.io/api/news?id=d5b3ebfc45df52df8d91729aba0c9d6a8fd7fb54d56ed8d9d3f18247aeef7b26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748711661,
      "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports 27% Reduction In COPD Exacerbations In Phase 3 Trial",
      "id": 134920454,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) announced favorable Phase 3 trial results for itepekimab and entered a significant licensing agreement with Telesis Bio, enhancing its R&D capabilities. Despite these positive developments, the company's shares fell by 17% last week. In contrast, the broader market rose by 1.7%. This divergence might suggest that the market's reaction to Regeneron's news was mixed or that other factors were at play. While the trial success and new partnership could...",
      "url": "https://finnhub.io/api/news?id=d5b3ebfc45df52df8d91729aba0c9d6a8fd7fb54d56ed8d9d3f18247aeef7b26"
    }
  },
  {
    "ts": null,
    "headline": "Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing",
    "summary": "Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant recurrence, respectively, compared to placebo Detailed results presented in an oral session at the 2025 American Society of Clinical Oncology Annual Meeting and simultaneously published in the New England Journal of Medicine Regulatory applications have been submitted in the United St",
    "url": "https://finnhub.io/api/news?id=a03edb6dd13fed3f04f9ffbaa8fc3c621c0575cb5c4d9bcb355a652afca76e32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748693040,
      "headline": "Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing",
      "id": 134918308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant recurrence, respectively, compared to placebo Detailed results presented in an oral session at the 2025 American Society of Clinical Oncology Annual Meeting and simultaneously published in the New England Journal of Medicine Regulatory applications have been submitted in the United St",
      "url": "https://finnhub.io/api/news?id=a03edb6dd13fed3f04f9ffbaa8fc3c621c0575cb5c4d9bcb355a652afca76e32"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc Says Libtayo Shows 68% Reduction In Risk Of Disease Recurrence Or Death",
    "summary": "Regeneron Pharmaceuticals Inc: * REGENERON PHARMACEUTICALS INC - LIBTAYO SHOWS 68%REDUCTION INRISK OF DISEASE RECURRENCE OR DEATH * REGENERON PHARMACEUTICALS INC -...",
    "url": "https://finnhub.io/api/news?id=63cfe691dacc1a6c4c3b28e2115b22bcfa839922513ab1b4feaeae07eff9a8ca",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748679252,
      "headline": "Regeneron Pharmaceuticals Inc Says Libtayo Shows 68% Reduction In Risk Of Disease Recurrence Or Death",
      "id": 134917840,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Regeneron Pharmaceuticals Inc: * REGENERON PHARMACEUTICALS INC - LIBTAYO SHOWS 68%REDUCTION INRISK OF DISEASE RECURRENCE OR DEATH * REGENERON PHARMACEUTICALS INC -...",
      "url": "https://finnhub.io/api/news?id=63cfe691dacc1a6c4c3b28e2115b22bcfa839922513ab1b4feaeae07eff9a8ca"
    }
  },
  {
    "ts": null,
    "headline": "abrdn Life Sciences Investors Q1 2025 Commentary",
    "summary": "abrdn Life Sciences Investors Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=6a43801cb46ae43d45b78fba22426c61b25efdf36ba75aa6357f4220e9041fb1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748650800,
      "headline": "abrdn Life Sciences Investors Q1 2025 Commentary",
      "id": 134911124,
      "image": "",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=6a43801cb46ae43d45b78fba22426c61b25efdf36ba75aa6357f4220e9041fb1"
    }
  }
]